Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback
Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback
SRRK shares surged over 360% on Oct. 7 after apitegromab met the main goal of a late-stage trial; shares have doubled YTD.Drugmaker $Scholar Rock (SRRK.US)$'s shares were trading more than 33% higher just past 11:55 am ET Monday at $40.04.
制药商 $Scholar Rock (SRRK.US)$美国东部时间周一上午11点55分过后，其股价上涨了33％以上，至40.04美元。
The company's rival $Biohaven (BHVN.US)$ said on Monday its experimental treatment for a rare neuromuscular disorder failed to meet the main goal of improving patients' motor function in a late-stage trial.
该公司的竞争对手 $Biohaven (BHVN.US)$ 周一表示，在一项后期试验中，其对一种罕见神经肌肉疾病的实验治疗未能实现改善患者运动功能的主要目标。
Truist analysts raise their peak sales estimate on apitegromab, SRRK's drug for the same disorder, called spinal muscular atrophy, to $1.5 bln from $1.2 bln after Biohaven's announcement, reported Reuters.
路透社报道，Truist分析师将SRRK治疗相同疾病（称为脊髓性肌萎缩症）的药物apitegromab的峰值销售额估计从Biohaven宣布后的12亿美元上调至15亿美元。
SRRK shares surged over 360% on Oct. 7 after apitegromab met the main goal of a late-stage trial; shares have doubled YTD.
在apitegromab实现后期试验的主要目标之后，sRK股价在10月7日飙升了360％以上；股价迄今已翻了一番。
